The long-acting COX-2 inhibitor mavacoxib (Trocoxil™) has anti-proliferative and pro-apoptotic effects on canine cancer cell lines and cancer stem cells in vitro

BACKGROUND: The NSAID mavacoxib (Trocoxcil™) is a recently described selective COX-2 inhibitor used for the management of inflammatory disease in dogs. It has a long plasma half-life, requiring less frequent dosing and supporting increased owner compliance in treating their dogs. Although the use of...

Descripción completa

Detalles Bibliográficos
Autores principales: Pang, Lisa Y, Argyle, Sally A, Kamida, Ayako, Morrison, Katherine O’Neill, Argyle, David J
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2014
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4172958/
https://www.ncbi.nlm.nih.gov/pubmed/25190452
http://dx.doi.org/10.1186/s12917-014-0184-9

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4172958/
https://www.ncbi.nlm.nih.gov/pubmed/25190452
http://dx.doi.org/10.1186/s12917-014-0184-9

Ejemplares similares